TY - JOUR
T1 - Parathyroid Hormone Shifts Cell Fate of a Leptin Receptor-Marked Stromal Population from Adipogenic to Osteoblastic Lineage
AU - Yang, Mengyu
AU - Arai, Atsushi
AU - Udagawa, Nobuyuki
AU - Zhao, Lijuan
AU - Nishida, Daisuke
AU - Murakami, Kohei
AU - Hiraga, Toru
AU - Takao-Kawabata, Ryoko
AU - Matsuo, Koichi
AU - Komori, Toshihisa
AU - Kobayashi, Yasuhiro
AU - Takahashi, Naoyuki
AU - Isogai, Yukihiro
AU - Ishizuya, Toshinori
AU - Yamaguchi, Akira
AU - Mizoguchi, Toshihide
N1 - Funding Information:
We acknowledge Asahi Kasei Pharma Co., Ltd., for providing hPTH (1-34) and A Iwadare for technical assistance. This work was supported by Grants-in-Aid from the Japan Society for the Promotion of Science (JSPS) KAKENHI (17H04374 and 16KK0190 to TM, 16K11798 to AA, and 16H05508 to NU), Private University Branding Project of Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan, Tokyo Dental College Branding Project for Multidisciplinary Research Center for Jaw Disease (MRCJD), Naito Foundation Natural Science (TM), Takeda Science Foundation (TM), and Mitsui Life Social Welfare Foundation (TM). Authors' roles: MY, AA, and TM contributed to the experiments. ZL, DN, and TH supported the cell sorting, imaging, and real-time PCR analyses. TK and KMa generated the genetic mice. KMu, RT-K, YI, TI, and AY contributed to analysis of PTH-treated OVX rats and mice. NU, YK, and NT contributed to data analysis and scientific comments. TM and AY designed and supervised the project. MY and TM wrote the manuscript.
Publisher Copyright:
© 2019 American Society for Bone and Mineral Research
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Intermittent parathyroid hormone (iPTH) treatment induces bone anabolic effects that result in the recovery of osteoporotic bone loss. Human PTH is usually given to osteoporotic patients because it induces osteoblastogenesis. However, the mechanism by which PTH stimulates the expansion of stromal cell populations and their maturation toward the osteoblastic cell lineage has not be elucidated. Mouse genetic lineage tracing revealed that iPTH treatment induced osteoblastic differentiation of bone marrow (BM) mesenchymal stem and progenitor cells (MSPCs), which carried the leptin receptor (LepR)-Cre. Although these findings suggested that part of the PTH-induced bone anabolic action is exerted because of osteoblastic commitment of MSPCs, little is known about the in vivo mechanistic details of these processes. Here, we showed that LepR+MSPCs differentiated into type I collagen (Col1)+ mature osteoblasts in response to iPTH treatment. Along with osteoblastogenesis, the number of Col1+ mature osteoblasts increased around the bone surface, although most of them were characterized as quiescent cells. However, the number of LepR-Cre-marked lineage cells in a proliferative state also increased in the vicinity of bone tissue after iPTH treatment. The expression levels of SP7/osterix (Osx) and Col1, which are markers for osteoblasts, were also increased in the LepR+MSPCs population in response to iPTH treatment. In contrast, the expression levels of Cebpb, Pparg, and Zfp467, which are adipocyte markers, decreased in this population. Consistent with these results, iPTH treatment inhibited 5-fluorouracil- or ovariectomy (OVX)-induced LepR+MSPC-derived adipogenesis in BM and increased LepR+MSPC-derived osteoblasts, even under the adipocyte-induced conditions. Treatment of OVX rats with iPTH significantly affected the osteoporotic bone tissue and expansion of the BM adipose tissue. These results indicated that iPTH treatment induced transient proliferation of the LepR+MSPCs and skewed their lineage differentiation from adipocytes toward osteoblasts, resulting in an expanded, quiescent, and mature osteoblast population.
AB - Intermittent parathyroid hormone (iPTH) treatment induces bone anabolic effects that result in the recovery of osteoporotic bone loss. Human PTH is usually given to osteoporotic patients because it induces osteoblastogenesis. However, the mechanism by which PTH stimulates the expansion of stromal cell populations and their maturation toward the osteoblastic cell lineage has not be elucidated. Mouse genetic lineage tracing revealed that iPTH treatment induced osteoblastic differentiation of bone marrow (BM) mesenchymal stem and progenitor cells (MSPCs), which carried the leptin receptor (LepR)-Cre. Although these findings suggested that part of the PTH-induced bone anabolic action is exerted because of osteoblastic commitment of MSPCs, little is known about the in vivo mechanistic details of these processes. Here, we showed that LepR+MSPCs differentiated into type I collagen (Col1)+ mature osteoblasts in response to iPTH treatment. Along with osteoblastogenesis, the number of Col1+ mature osteoblasts increased around the bone surface, although most of them were characterized as quiescent cells. However, the number of LepR-Cre-marked lineage cells in a proliferative state also increased in the vicinity of bone tissue after iPTH treatment. The expression levels of SP7/osterix (Osx) and Col1, which are markers for osteoblasts, were also increased in the LepR+MSPCs population in response to iPTH treatment. In contrast, the expression levels of Cebpb, Pparg, and Zfp467, which are adipocyte markers, decreased in this population. Consistent with these results, iPTH treatment inhibited 5-fluorouracil- or ovariectomy (OVX)-induced LepR+MSPC-derived adipogenesis in BM and increased LepR+MSPC-derived osteoblasts, even under the adipocyte-induced conditions. Treatment of OVX rats with iPTH significantly affected the osteoporotic bone tissue and expansion of the BM adipose tissue. These results indicated that iPTH treatment induced transient proliferation of the LepR+MSPCs and skewed their lineage differentiation from adipocytes toward osteoblasts, resulting in an expanded, quiescent, and mature osteoblast population.
KW - ADIPOCYTES
KW - INTERMITTENT PARATHYROID HORMONE
KW - LEPTIN RECEPTOR
KW - OSTEOBLASTS
KW - STEM CELLS
UR - http://www.scopus.com/inward/record.url?scp=85070069820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070069820&partnerID=8YFLogxK
U2 - 10.1002/jbmr.3811
DO - 10.1002/jbmr.3811
M3 - Article
C2 - 31173642
AN - SCOPUS:85070069820
SN - 0884-0431
VL - 34
SP - 1952
EP - 1963
JO - Journal of Bone and Mineral Research
JF - Journal of Bone and Mineral Research
IS - 10
ER -